Postoperative Pain Industry Outlook, 2020-2028 – Approval of Therapies such as Maxigesic, HTX-011, Olinvo, CR845 Will Create a Positive Impact on the…

DUBLIN, Feb. 14, 2020 /PRNewswire/ -- The "Postoperative Pain - Market Insights, Epidemiology and Market Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.

The Postoperative Pain Report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Postoperative Pain in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Postoperative Pain from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Postoperative Pain Epidemiology

According to the review article by Tong J Gen (2017), surgery and anesthesia are critical health care services that reduce the risk of death and disability among millions worldwide each year, and the need for these services is expected to continue to increase over the next decade. Globally, nearly 313 million operations were performed in 2012. Although possibly life-saving, surgery is also related to potential harm, which normally includes pain during and after the procedure.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Postoperative Pain in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

The disease epidemiology covered in the report is segmented by:

As per the analysis, in 2017 the total number of incident cases of postoperative pain in the US was 40,314,731. The main reasons behind increased cases are due to increase morbidity, reduced physical function and quality of life, increased cost of care, bad recovery, preexisting pain, and prolonged opioid use during and after hospitalization.

Further, according to the publisher, in 2017, it is estimated that the severity-specific incident cases of postoperative pain in France were 1,194,644, 1,439,003 and 828,105 in mild, moderate and severe cases respectively. Additionally, Japan was observed with 12,134,677 incident cases for postoperative pain in 2017.

A study was conducted by Marinangeli et al. (2009) to know the treatment of acute pain in the prehospital emergency setting remains a significant problem. The study evaluated the incidence, site, and possible cause of acute pain in the prehospital period and also the current state of prehospital pain management by assessing analgesic availability in emergency vehicles in Italy. The study concluded that pain symptoms were present in approximately two-thirds of the patients (n = 383) and ranked as moderate to unbearable in 41.75%.

Results of the analgesic availability survey specify that 10.6% of the ambulance services carry no pain killers (including nonsteroidal anti-inflammatory drugs [NSAIDs] and/or paracetamol) and 11.5% are without an opioid. The pain evaluation was calculated which showed that 32.5% had no pain, 22% showed slight pain, 26.5% showed moderate pain, 12% patient felt severe pain, 3.25% patient could not bear the pain, and 3.75% patient were not defined in the scale (Marinangeli et al., 2009).

Postoperative Pain Drug Chapters

This segment of the Postoperative Pain report encloses a detailed analysis of the drugs that are expected to be launched in other regions. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Postoperative Pain and awareness of the disease. The overall dynamics of the Postoperative Pain market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Heron Therapeutics, Cara Therapeutics, Trevena and others will significantly increase the market during the forecast period (2019-2028).

Postoperative Pain Market Outlook

Currently, the treatment pattern consists of different classes of drugs that are classified into pharmacologic and nonpharmacological therapies. The pharmacological therapies include analgesics that are further segregated into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen respectively. The acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids.

Further, nonpharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM).

Opioids are a large group of pain-relieving drugs that are used for reducing the pain in the postoperative cases. These drugs majorly include fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, and tramadol. Also, non-steroidal anti-inflammatory drugs (NSAIDs) are a sensible choice because of their effectiveness after surgical procedures. However, before surgeons start prescribing NSAIDs in place of opioids, it is crucial first to understand their potential post-surgical complications.

NSAIDs provide anti-inflammatory, antipyretic, analgesic and thrombotic effects through the inhibition of the enzymes cyclooxygenases 1 and 2 (COX-1 and COX-2). Although several generics are available for NSAIDs and presence of generics in the market is due to patent expiration. Paracetamol is the most commonly used analgesic with analgesic and antipyretic action. Even though it has been widely available for a long time, its exact mechanism of action is still unknown.

In addition to this, in September 2015, Zalviso was approved by the European Commission (EC) for the management of acute moderate-to-severe pain in adult patients in the hospital setting. The drug is a synthetic, potent opioid with highly selective binding to -opioid receptors. Another approved drug in the European Union is Maxigesic, which is approved in Austria, Belgium, Croatia, France, Germany, Luxembourg, Netherlands, Portugal, and Spain in May 2017. The drug reduces fever and provides temporary relief of pain associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu.

Dsuvia is an opioid agonist contains sufentanil and is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. Dsuvia is administered in the form of the tablet sublingually to the patient. Also, it is approved as a brand name Dzuveo in Europe and is effective in reducing severe pain following surgeries.

The postoperative pain pipeline possesses potential drugs in late and mid developments to be launched in the near future. The major key players include Olinvo (Trevena), HTX-011 (Heron Therapeutics), and CR845/Difelikefalin (Cara Therapeutics).

Olinvo (Trevena) is a novel G protein biased (selective) mu-opioid receptor (MOR) ligand which is in development for the management of moderate-to-severe acute pain in hospitals or other controlled clinical settings where IV opioid therapy is warranted. The drug is currently in phase III clinical developmental trial.

Heron Therapeutics is developing a potent drug HTX-011 (bupivacaine and meloxicam) which is in phase III developmental trial. The drug is a fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. In December 2018, the US FDA accepted the new drug application (NDA) for HTX-011 and also granted a Priority Review designation.

This segment gives a thorough detail of market trend of each therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Postoperative Pain in the 7MM is expected to change from 2019-2028.

Postoperative Pain Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Approval of therapies for Postoperative Pain such as Maxigesic (AcelRx Pharmaceuticals; to be launched in US and Japan), HTX-011 (Heron Therapeutics; to be launched in US, EU and Japan), Olinvo (Trevena; to be launched in US, EU and Japan), CR845 (Cara Therapeutics; to be launched in US, EU and Japan), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Postoperative Pain market.

The market is anticipated to show an extensive boost due to projected label expansion of the current therapies and emergence of potential pipeline products as approved therapies in the near future. The market size of Postoperative in the seven major markets in 2017 was USD 1,067.82 Million in 2017. Japan accounts for the least market size in the 7MM during the forecast period 2017-2028, at a CAGR of 7.41% for the study period (2017-2028). Among the EU5 countries, Germany had the highest market size with USD 49.89 Million in 2017, while Spain had the lowest market size of postoperative pain.

Report Insights

Key Strengths

Report Assessment

Key Benefits

Companies Mentioned

Key Topics Covered

1. Key Insights

2. Postoperative Pain Market Overview at a Glance2.1. Market Share (%) Distribution of Postoperative Pain in 20172.2. Market Share (%) Distribution of Postoperative Pain in 2028

3. Disease Background and Overview: Postoperative Pain3.1. Introduction3.2. Transition from Acute to Chronic Pain3.2.1. Elective or Planned Procedures3.2.2. Common Types of Acute Postoperative Pains3.3. Pathophysiology of Acute Pain3.3.1. Formation of reflexes in postoperative pain3.3.2. Negative effects of postoperative pain on various organ systems3.3.3. Psychological effects of postoperative pain3.3.4. Late effects of insufficient postoperative analgesia3.3.5. Chronic postoperative pain3.4. Factors affecting postoperative pain3.5. Diagnosis of Postoperative Pain3.5.1. Medical history, physical examination, and specific evaluation of pain3.5.2. Measuring pain3.5.3. Various Grading Scales used for Diagnosis of Acute Pain3.5.4. Verbal methods of pain assessment3.5.5. Multidimensional methods of pain assessment3.5.6. Nonverbal methods of pain assessment3.6. Diagnostic Algorithm3.7. Guidelines3.7.1. Guidelines on the Management of Postoperative Pain3.7.2. Goals and Elements of the Initial Assessment

4. Epidemiology and Patient Population4.1. Key Findings4.2. Total number of Incident cases of Postoperative Pain in the 7MM

5. Epidemiology of Postoperative Pain in the 7MM5.1. Assumptions and Rationale5.2. United States5.2.1. Total number of surgical procedures in the US5.2.2. Total number of Postoperative Pain Incident cases in the US5.2.3. Severity-specific Postoperative Pain incident cases in the US5.3. Germany5.4. France5.5. Italy5.6. Spain5.7. United Kingdom5.8. Japan

6. Treatment6.1.1. Pharmacological Therapies6.1.2. Multimodal analgesia6.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)6.1.4. Opioids6.1.5. Non-opioid analgesics6.1.6. Procedure-specific analgesia6.1.7. Regional anesthesia6.1.8. Non-Pharmacological Methods to Treat Acute Pain6.1.9. Physical methods6.1.10. Intravenous Patient-Controlled Analgesia (PCA)6.1.11. Nerve Blocks6.1.12. Pediatric Pain Management6.2. Treatment Algorithm for Acute Postoperative Pain

7. Guidelines for Acute Pain7.1.1. Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy (2017)7.1.2. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)

8. Unmet Needs

9. Marketed Drugs9.1. Marketed Drugs Key-cross Competition9.2. Zalviso: AcelRx Pharmaceuticals9.2.1. Product Description9.2.2. Regulatory Milestones9.2.3. Other Developmental activities9.2.4. Clinical Development9.2.5. Safety and Efficacy9.2.6. Product Profile9.3. Maxigesic: AFT Pharmaceuticals9.4. Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals9.5. Dexketoprofen Tramadol: Menarini Group

10. Emerging Drugs10.1. Key Cross Competition10.2. Olinvo (Oliceridine injection or TRV130): Trevena10.2.1. Product Description10.2.2. Other Development Activities10.2.3. Clinical Development10.2.4. Safety and Efficacy10.2.5. Product Profile10.3. HTX-011: Heron Therapeutics10.4. CR845/Difelikefalin: Cara Therapeutics10.5. NTM-001: Neumentum Pharmaceuticals10.6. PF-05089771: Pfizer

11. Postoperative Pain: 7 Major Market Analysis11.1. Key Findings11.2. Forecasting Parameters11.3. Market Size of Postoperative Pain in the 7MM Countries

12. 7MM Market Outlook12.1. Expected Approval: Emerging Therapies12.2. United States12.2.1. Total Market size of Postoperative Pain12.2.2. Market Size by Therapies12.3. Germany12.4. France12.5. Italy12.6. Spain12.7. United Kingdom12.8. Japan Market Size

13. Market Drivers

14. Market Barriers

For more information about this report visit https://www.researchandmarkets.com/r/ita38l

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:

Postoperative Pain Industry Outlook, 2020-2028 - Approval of Therapies such as Maxigesic, HTX-011, Olinvo, CR845 Will Create a Positive Impact on the...